What You Should Know:
– L7 Informatics, a leader in software for life sciences that delivers a flexible end-to-end platform for precision healthcare, today announced a $38M investment led by Banneker Partners with participation from its pre-existing investors.
– The company will use the new funding to accelerate product development, expand L7|ESP’s global reach, and build on L7’s outstanding customer support.
Precision healthcare offers significant improvements in effectiveness for life-threatening diseases and degenerative conditions. Over the last decade, personalized healthcare has spread beyond oncology and now comprises almost half of all new drugs in development. The global precision medicine market size is predicted to triple in the next decade, from $66 billion in 2021 to $196 billion in 2030.
L7|ESP for Precision Medicine
L7’s Enterprise Science Platform (L7|ESP) is the only regulatory compliant platform designed to manage the unique complexities of precision healthcare across scientific research, diagnostics, therapeutics, and medicine. The platform has native applications including LIMS, ELN, MES, and inventory. It can integrate with existing third-party applications, lab instruments, and devices to capture all data in a single data model. It has a low-code/no-code workflow designer and hundreds of pre-built connectors to enable rapid time to value and end-to-end automation. By leveraging a single data model, L7|ESP enables advanced bioinformatics, AI, and ML to offer novel scientific and operational insights.
